Cuba CECMED Medical Device Registry Teardown: 4,739 Registrations

A quantitative teardown of Cuba's CECMED medical device registry of 4,739 approved registrations, analyzing the mix of global suppliers, local biotech institutes, and clinical specialties.

Understanding Cuba's Healthcare and Biotechnology Model

Cuba represents a unique and highly centralized healthcare and medical technology market. Under its socialist state-directed economic model, all health services are publicly funded and managed by the Ministry of Public Health (Ministerio de Salud Pública, MINSAP). Cuba is globally recognized for its emphasis on primary healthcare and preventive medicine, achieving health outcomes comparable to developed nations despite severe resource constraints and long-standing economic embargoes.

To support this system, Cuba has pursued a deliberate, decades-long strategy of scientific self-reliance. Starting in the 1980s, the state invested heavily in building a domestic biotechnology and medical device sector, concentrated today within the state-owned conglomerate BioCubaFarma. This sector was designed not only to produce affordable pharmaceuticals but also to develop specialized diagnostic platforms, neurotechnology, medical electronics, and software tailored to local clinical realities.

However, Cuba cannot produce all necessary medical technologies domestically. For complex, specialized therapeutic areas—such as high-end cardiology, implantable orthopedics, advanced imaging, and general surgical instrumentation—the country relies on imports from global manufacturers.

This teardown provides a quantitative analysis of Cuba’s medical device and IVD register based on the official database from the Center for State Control of Medicines, Equipment and Medical Devices (Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos, CECMED). We break down the clinical specialty distributions, analyze manufacturer concentration, examine the role of local research institutes, detail the CECMED registration pathway, and compare the Cuban regulatory framework with other Latin American nations.

The Role of CECMED and Sanitary Registration Guidelines

CECMED is Cuba's national regulatory authority, responsible for evaluating and authorizing all medicines, medical devices, diagnostic reagents, and health products before they can be imported, manufactured, or used in the country. Established in 1989, CECMED operates under the authority of MINSAP and is recognized by the Pan American Health Organization (PAHO) and the World Health Organization (WHO) as a Level 4 Regulatory Authority—the highest level of regulatory competency in the Americas.

Sanitary registration for medical devices in Cuba is governed by several key regulatory texts:

Regulación 11/2012 (Directrices para el Registro de Dispositivos Médicos): Sets out the general requirements, application procedures, and dossier checklists for medical device registration.
Regulación 12/2012 (Clasificación de Dispositivos Médicos por Riesgo): Establishes the risk-classification rules (Classes I, II, III, and IV) based on the degree of invasiveness, duration of contact, and potential harm, aligning closely with Global Harmonization Task Force (GHTF) and IMDRF guidelines.
Regulación 45/2007 (Buenas Prácticas de Fabricación de Dispositivos Médicos): Mandates quality system requirements similar to ISO 13485 for manufacturers.

To place a medical device on the Cuban market, a manufacturer—whether domestic or foreign—must secure a Sanitary Registration Certificate (Certificado de Registro Sanitario). Foreign manufacturers must appoint a licensed local Cuban representative (such as a state import agency or distributor) to act as their legal liaison, submit the technical dossier, and manage the registration lifecycle.

Quantitative Teardown of the 4,739 Approved Registrations

An analysis of the CECMED medical device registry reveals a robust database of approved clinical technologies. As of the July 8, 2026 registry export, the dataset contains 4,739 approved medical device and IVD registrations.

This section details the clinical specialty mix and highlights how public health priorities shape the distribution of registered medical technologies.

Clinical Specialty Mix

Every medical device registration in the CECMED database is classified under a designated medical specialty (especialidad). Grouping the registrations by specialty reveals the therapeutic areas that command the most regulatory and commercial activity:

Clinical Specialty	Spanish Term	Registered Products	Share of Registry
General Surgery	CIRUGIA GENERAL	404	8.5%
Cardiology	CARDIOLOGIA	357	7.5%
Imaging / Radiology	IMAGENOLOGIA	192	4.1%
Ophthalmology	OFTALMOLOGIA	187	3.9%
Clinical Laboratory / IVD	LABORATORIO CLINICO	186	3.9%
Nursing / General Consumables	ENFERMERIA	183	3.9%
Stomatology / Dental	ESTOMATOLOGIA GENERAL	170	3.6%
Primary Care / General Medicine	MEDICINA GENERAL INTEGRAL	125	2.6%
Nephrology	NEFROLOGIA	122	2.6%
Other Specialties	Various	2,138	45.1%
Unclassified / Blank	—	385	8.1%
Total		4,739	100.0%

Key Insights from the Specialty Distribution:

General Surgery (8.5%): With 404 registered products, general surgery represents the largest identified specialty. This includes basic surgical instruments, sutures, trocars, and specialized disposable products used across Cuba's hospital network.
Cardiology (7.5%): Cardiology accounts for 357 registrations, reflecting the high public health priority placed on cardiovascular disease (the leading cause of death in Cuba). This segment includes high-risk Class III and IV implantable devices, such as pacemakers, coronary stents, catheters, and heart valves, which are predominantly imported.
Diagnostics and Imaging (8.0% combined): Imaging (192) and Clinical Laboratory (186) represent a combined 8.0% of the registry. This underlines the importance of diagnostics in Cuba's preventive medicine model, supporting local screening networks and hospital laboratories.
Unclassified Entries (8.1%): The 385 blank specialty fields represent generic consumables, hospital furniture, or legacy registrations where specific clinical codes were not recorded in the central database.

Global Manufacturers in Cuba

Although Cuba has built a respectable domestic biotechnology sector, it remains highly dependent on foreign manufacturers for advanced medical devices, diagnostics, and sterile implants. The embargo limits direct trade with US-based entities, but many multinational device manufacturers route their registrations through European, Asian, or Latin American subsidiaries.

Analyzing the manufacturer distribution (fabricante_filled) in the CECMED registry shows a high concentration of global device conglomerates:

Manufacturer Group	Headquarter Country	Active Registrations	Share of Registry
B. Braun Group (inc. B. Braun Melsungen, Aesculap, and Surgical S.A.)	Germany / Spain	208	4.4%
Biotronik Group (inc. Biotronik AG and Biotronik SE)	Germany / Switzerland	98	2.1%
Boston Scientific Corporation	United States	71	1.5%
Medtronic Inc.	United States	66	1.4%
Assut Europe S.p.A.	Italy	51	1.1%
Reda Instrumente GmbH	Germany	46	1.0%
Merit Medical Systems, Inc.	United States	36	0.8%
Roche Diagnostics GmbH	Germany	35	0.7%
Romsons International	India	35	0.7%
Silmag S.A.	Argentina	33	0.7%
Geuder A.G.	Germany	33	0.7%
St. Jude Medical (Abbott)	United States	29	0.6%

Strategic Manufacturer Observations:

German Leadership: German firms are prominent in Cuba's registry. The B. Braun Group leads all foreign suppliers with 208 registrations (131 for B. Braun Melsungen, 61 for Aesculap, and 16 for B. Braun Surgical). Biotronik, a leader in pacemakers and vascular intervention, holds 98 registrations, while specialized ophthalmic and surgical instrument makers like Geuder A.G. (33) and Reda Instrumente (46) also hold significant portfolios. German engineering reputation and flexible trading structures have allowed these firms to maintain a stable, decades-long presence.
US Multinational Portfolios: Despite the US embargo, major US medtech companies hold significant registration footprints. Boston Scientific (71), Medtronic (66), Merit Medical (36), and St. Jude Medical/Abbott (29) are active. These registrations are typically managed by their European headquarters (e.g., Medtronic Bakken Research Center in the Netherlands or Boston Scientific in France/Germany) and authorized under specific humanitarian exemptions for medicine and medical supplies.
Emerging Market Entrants: Manufacturers from India (e.g., Romsons International with 35 registrations) and Argentina (e.g., Silmag S.A. with 33 registrations) have successfully established market share by offering cost-effective consumables and disposable devices that fit Cuba's public procurement budgets.

Cuba's Domestic Biotechnology and Medical Technology Integration

The most unique aspect of Cuba’s medical device registry is the prominent role played by domestic, state-backed research institutes and manufacturers. Within the top 50 manufacturers, several local Cuban entities appear with registration volumes that rival global conglomerates.

In total, approximately 251 registrations (5.3% of the registry) are held by domestic Cuban manufacturers. This domestic sector is highly integrated with Cuba's national health system, providing targeted clinical solutions designed to reduce import dependence.

The primary domestic medtech entities identified in the registry include:

1. Centro de Inmunoensayo (52 Registrations)

The Center for Immunoassays is one of the crown jewels of Cuba's biotechnology sector. It is responsible for developing and manufacturing the SUMA (Sistema Ultra Micro Analítico) platform. SUMA is an micro-ELISA diagnostic system designed to perform large-scale, low-cost screening.

Clinical Focus: SUMA is utilized for Cuba's national prenatal and neonatal screening programs, detecting congenital hypothyroidism, congenital adrenal hyperplasia, cystic fibrosis, and galactosemia in newborns. It is also used to screen blood donations for HIV, Hepatitis B, Hepatitis C, and Chagas disease.
Registry Footprint: The center holds 52 registrations for specialized diagnostic kits, microplate readers, and automated pipetting systems.

2. Centro de Neurociencias de Cuba (CNEURO) (67 Registrations)

CNEURO is a pioneer in neurotechnology, brain mapping, and medical software. The center holds 67 registrations under two database names: CNEURO (41) and CNC (26).

Key Technologies: CNEURO developed the Neurónica and AUDIX systems. Neurónica is an advanced electroencephalography (EEG) and electromyography (EMG) platform used for clinical neurophysiology, while AUDIX is an automated screening system for infant hearing loss. CNEURO also manufactured local mechanical ventilators during global supply chain crises.
Registry Footprint: Comprises specialized software modules, electrodes, stimulators, and complete neurodiagnostic workstations.

3. Combiomed Tecnología Médica Digital (47 Registrations)

Combiomed is the primary manufacturer of cardiovascular monitors, defibrillators, and electronic patient-care equipment in Cuba.

Key Technologies: Its flagship products include the Doctus series of multi-parameter patient monitors, the CARDIODEF defibrillator-monitor range, and portable electrocardiographs (ECG) used in primary care clinics (Consultorios del Médico de la Familia).
Registry Footprint: 47 registrations covering patient monitors, ECG electrodes, pulse oximeters, and automated blood pressure monitors.

4. Instituto Central de Investigación Digital (ICID) (67 Registrations)

The ICID (registered under both "Empresa de Tecnología Médica Digital ICID" with 47 registrations and "Instituto Central de Investigación Digital ICID" with 20 registrations) focuses on hospital equipment, infant incubators, and clinical software systems.

Key Technologies: ICID developed the DIAPLAN hemodialysis support systems and the MEDICID neurophysiological workstation in collaboration with CNEURO, alongside neonatal incubators and infusion pumps.
Registry Footprint: 67 registrations for dialysis consumables, neonatal care equipment, and medical software.

5. Sibling Domestic Players: Acrilest and CEADEN

Combinado de Productos Dentales Acrilest (29 Registrations): A state-owned enterprise specialized in manufacturing acrylic resins, artificial teeth, and dental consumables to support the national dental network (Estomatología).
Centro de Aplicaciones Tecnológicas y Desarrollo Nuclear (CEADEN) (16 Registrations): Focuses on applying nuclear and physical technologies to medicine, including registered medical lasers and specialized radiation-protection equipment.

This integrated model allows Cuba's healthcare system to deploy high-value diagnostics (SUMA) and monitoring systems (Combiomed) across its entire population at a fraction of the import cost, securing the system's baseline resilience.

The Step-by-Step CECMED Registration Process for Foreign Entrants

For foreign medical device manufacturers, registering a product with CECMED is a prerequisite for participating in MINSAP public tenders (which are centralized through state purchasing agencies like MediCuba). The registration process requires demonstrating high quality, safety, and clinical efficacy.

[Phase 1: Local Representation] -> [Phase 2: Dossier Preparation] -> [Phase 3: Clinical Evaluation] -> [Phase 4: Regulatory Submission] -> [Phase 5: Approval & Maintenance]

Phase 1: Establish Local Representation

Foreign firms cannot submit registration dossiers directly to CECMED. They must sign a representation agreement with an authorized local entity. This representative is typically:

A state-owned importing agency (e.g., MediCuba S.A. for medical equipment and consumables).
A specialized local commercial representative authorized by the Ministry of Foreign Trade and Investment (MINCEX).
The local representative acts as the license holder (titular del registro) in Cuba.

Phase 2: Technical Dossier Preparation

The manufacturer must compile a comprehensive technical file in Spanish. In accordance with CECMED Regulación 11/2012, this dossier must include:

Administrative Data: Application form, ISO 13485 certificate of the manufacturer, and free sale certificate (FSC) from the country of origin. Crucially, all foreign official documents must be legalized or apostilled at the Cuban embassy or consulate in the manufacturer's home country.
Product Specifications: Detailed description of design, raw materials, biocompatibility (ISO 10993), sterilization validation, shelf-life testing, and software validation when applicable.
Risk Management: Risk assessment report following ISO 14971.

Phase 3: Clinical Evaluation and Testing

Cuba places a heavy emphasis on clinical validation. Depending on the risk class:

Class I and IIa: CECMED usually accepts clinical data from foreign clinical trials and literature reviews, provided they are supported by CE marking or FDA clearance.
Class IIb, III, and IV: CECMED often requires a local clinical evaluation. This may involve:
- Lab testing of the device at a designated Cuban scientific institute (e.g., testing neurophysiology equipment at CNEURO).
- A local clinical trial or validation study conducted in a Cuban university hospital under the supervision of MINSAP.

Phase 4: Regulatory Submission and Evaluation

Once the representative submits the dossier, CECMED conducts a multi-stage review:

Admissibility Review: Verification that all required administrative and technical documents are present.
Technical Evaluation: In-depth review of the product's safety and performance data by CECMED's expert committee.
Facility Inspection: For high-risk devices (Class III/IV) or domestic manufacturers, CECMED reserves the right to conduct a physical Good Manufacturing Practices (GMP) audit of the manufacturing facility. In practice, CECMED frequently waives audits for foreign manufacturers holding valid MDSAP or EU notified body certificates, but may request desk audits.

Phase 5: Approval and Maintenance

If the evaluation is positive, CECMED issues the Sanitary Registration Certificate.

Validity: The certificate is valid for exactly 5 years.
Renewal: Renewal applications must be submitted 6 months prior to expiry. The manufacturer must demonstrate that no significant design changes, major adverse events, or recalls have occurred during the registration period.

Latin American Regulatory Comparison

For regional regulatory directors, understanding how Cuba fits within the broader Latin American regulatory landscape is crucial.

Parameter	Cuba (CECMED)	Argentina (ANMAT)	Colombia (INVIMA)	Mexico (COFEPRIS)	Brazil (ANVISA)
Primary Model	Centralized State Approval	Reliance + Independent Review	Reliance + Fast-Track	Reliance + Equivalency Pathways	Independent Review + MDSAP
Risk Classes	Class I, II, III, IV	Class I, II, III, IV	Class I, IIa, IIb, III	Class I, II, III	Class I, II, III, IV
Local Representative Required?	Yes (State agency or authorized rep)	Yes (A.A.R. holder)	Yes (Importer of Record)	Yes (Sanitary Registry Holder)	Yes (BRH holder)
Registration Validity	5 Years	5 Years	10 Years	5 Years	Unlimited (for Cadastro/Registro)
Clinical Trial Requirements	Frequent for Class III/IV (local evaluation)	Rare (accepts foreign data)	Rare (accepts foreign data)	Rare (accepts foreign data)	Required for select Class III/IV implants
CE Mark/FDA Reliance	High (for Class I/II); Case-by-case (Class III/IV)	High	High	High (Equivalency Agreement)	High (accepts MDSAP for QMS audits)
Official Language	Spanish	Spanish	Spanish	Spanish	Portuguese

CECMED Vigilance and Post-Market Safety Guidelines

Once a medical device is successfully registered and commercialized in Cuba, it enters the post-market phase, where CECMED maintains active regulatory oversight. Cuba operates a centralized national medical device vigilance program (Tecnovigilancia), coordinated by CECMED's Vigilance and Post-Market Surveillance Department. Both the foreign manufacturer and the local sanitary registration holder (the Ivoirian importer or state purchasing agency) share legal responsibilities for monitoring the safety and clinical performance of the device in Cuban hospitals.

Mandatory Adverse Event Reporting

Under Regulación 11/2012, the local representative must establish a documented procedure to collect, evaluate, and report adverse events. The reporting timelines to CECMED are strictly defined:

Serious Adverse Events (SAE): Any incident that results in death, life-threatening illness or injury, permanent impairment, or requires clinical intervention to prevent permanent damage must be reported to CECMED within 15 calendar days of the representative becoming aware of the event.
Public Health Emergencies: If an adverse event represents an imminent public health hazard or a cluster of malfunctions is detected in a hospital network, the reporting window is shortened to 72 hours.
Non-Serious Events: Minor malfunctions or complaints must be logged by the importer and submitted to CECMED in aggregate quarterly reports.

Recall and Corrective Action Protocols

If a manufacturer initiates a global field safety corrective action (FSCA) or product recall:

Notification: The manufacturer must notify their local Cuban representative and CECMED simultaneously, providing the recall rationale, affected serial/batch numbers, and the proposed customer letter.
Action Plan: The local representative must submit an action plan to CECMED detailing how the affected devices will be quarantined, returned, or upgraded in Cuban hospitals.
Execution Reports: The representative must submit periodic progress reports and a final closure report to CECMED once all affected units in the country have been successfully mitigated.

Failure to comply with tecnovigilancia reporting or recall mandates can result in the suspension or permanent cancellation of the product's Sanitary Registration Certificate.

Frequently Asked Questions

How many medical devices are registered in Cuba's CECMED system?

As of the July 8, 2026 registry export, there are 4,739 approved medical device and IVD registrations active in Cuba.

Does CECMED accept CE marking or FDA clearance for medical device registration?

Yes, CECMED accepts CE mark certificates, FDA 510(k) clearances, and PMA approvals as part of the technical dossier. For Class I and Class IIa devices, these approvals are usually sufficient to satisfy safety and performance requirements. However, for Class IIb, III, and IV devices, CECMED may still require additional clinical data, local laboratory testing, or a local clinical validation study.

How long does the CECMED medical device registration process take?

The timeline varies depending on the device risk class and the completeness of the submission:

Class I / IIa: Approximately 6 to 9 months.
Class IIb / III / IV: Typically 12 to 18 months, especially if local clinical evaluations or testing are required by CECMED's technical committees.

Who is the leading medical device manufacturer in Cuba's registry?

The leading foreign manufacturer group is B. Braun (including B. Braun Melsungen, Aesculap, and B. Braun Surgical) with 208 registrations, representing 4.4% of the entire registry. The leading domestic manufacturer is the Centro de Inmunoensayo with 52 registrations for its micro-ELISA SUMA diagnostic platform.

What is the validity of a CECMED sanitary registration in Cuba?

A CECMED sanitary registration certificate is valid for exactly 5 years. Re-registration (renewal) must be requested 6 months before the certificate's expiration date.

Strategic Summary for Market Access

Navigating medical device registration and commercialization in Cuba requires a specialized approach. Foreign manufacturers should consider the following:

Leverage Regional Success: If your device holds active registration in Argentina, Brazil, or Mexico, highlight this in your dossier. CECMED's alignment with PAHO/WHO Level 4 criteria means they respect the reviews of peer Latin American regulators.
Anticipate Legalization Timelines: The requirement to legalize or apostille all foreign administrative documents at the Cuban consulate can add 2 to 4 months to your project timeline. Begin this process early.
Engage State Procurement Channels: Because MINSAP controls all healthcare delivery, your local representative is key. Ensure your representative is well-integrated with MediCuba S.A. to ensure your newly registered product is included in public procurement lists.
Respect the Domestic Niche: Understand that Cuba will prioritize its local biotechnology products (like Combiomed monitors or CNEURO neurodiagnostic systems) for primary care. Focus your import strategy on specialized, high-risk specialties (cardiology, orthopedics, oncology) where domestic alternatives do not exist.

Disclaimer: This analysis is based on the official register of approved medical devices and diagnostic reagents published by the Center for State Control of Medicines, Equipment and Medical Devices (CECMED) on July 8, 2026. Regulatory requirements are subject to change. Manufacturers should consult with qualified local regulatory counsel and their designated Cuban representatives before submitting registration dossiers or executing commercial agreements.

For broader regional regulatory context, see our Latin America medical device registration comparison guide. Sibling country register analyses are available at the Argentina ANMAT medical device register market analysis and Colombia INVIMA importer channel lock-in analysis.